Grizzly Research short GeneDx, says ‘actively committing widespread fraud’
Grizzly Research is short GeneDx (WGS), saying insiders attest that the company is “actively committing widespread fraud.” In a recently ...
GeneDx targeted in short report by Grizzly Research
In 2022, before changing its name from Sema4 to GeneDx, the company had a dispute with UnitedHealthcare, which resulted in a ...
GeneDx down 3% after Grizzly Research publishes short report, alleging fraud
EST GeneDx (WGS) down 3% after Grizzly Research publishes short report, alleging fraudMaximize Your Portfolio with Data Driven ...
GeneDx drops after short report; Wall Street analysts defend (update)
Adds analyst comment. GeneDX (NASDAQ:WGS) fell 4% after a short report from Grizzly Research on the genetic testing company. Grizzly Research disclosed that it's short shares of GeneDX (NASDAQ:WGS).
BTIG maintains GeneDx stock Buy rating, $95 target amid fraud claim
BTIG analysts stood firm on their positive stance towards GeneDx (NASDAQ:WGS), reiterating a Buy rating and a $95.00 price target for the company's stock. With analyst targets ranging from $70 to $118 ...
Yahoo Finance29d
GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of >22,000 Patients
These contributions, added to GeneDx’s years of dedicated research efforts, influenced the broadening of phenotypes, the discovery of new disease mechanisms and new modes of inheritance ...
pv magazine International3y
Renesola rejects allegations of fraudulent activities
According to U.S.-based Grizzly Research LLC, many of the company’s European solar projects appear not to exist. Renesola has said it will review the report and address the key inaccuracies with ...